Get started
Author

Arthur Coste

Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program
2024 · Aurore Perrot, Cyrille Hulin, et al. · Haematologica · 29
PDF
A retrospective longitudinal study of students’ residency choices at the French medical ranking exam
2025 · Arthur Coste, David Morland, et al. · BMC Medical Education · 4
PDF
Teclistamab in Elderly Patients With Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis of the French RetrosTECtive Cohort
2026 · A. Coste, S. Godet, et al. · eJHaem · 1
PDF
Prediction of 123I-FP-CIT SPECT Results from First Acquired Projections Using Artificial Intelligence
2025 · Wadi’ Othmani, Arthur Coste, et al. · Diagnostics · 1
PDF
Associations de l’acalabrutinib dans la leucémie lymphoïde chronique en première ligne
2026 · Arthur Coste, Anne Quinquenel · Bulletin du Cancer
L’odronextamab dans les lymphomes B diffus à grandes cellules et lymphomes folliculaires en rechute ou réfractaire en troisième ligne
2025 · Arthur Coste, Loïc Renaud · Bulletin du Cancer
P-065 Effectiveness and Safety of Teclistamab in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma: Results of the French Real-World RetrosTECtive Study
2024 · Aurore Perrot, Cyrille Hulin, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 7
Citation count: 35
H-index: 2
I10-index: 1
Year
Topic
Type